文献速递胸部肿瘤放疗放疗物理与技术

每日两次加速超分割再程放疗治疗胸部恶性肿瘤的疗效与安全性

Efficacy and safety of twice-daily accelerated hyperfractionated re-irradiation for thoracic malignancies.
PubMed 文献 · Radiother Oncol · 2025-09-10

INTRODUCTION: Balancing the demands for dose-escalated re-irradiation with toxicity to organs at risk (OARs) is a challenge.…

要点

  • 每日两次加速超分割再程放疗对胸部恶性肿瘤安全有效,局部控制持久且生存获益良好。
  • 15.6%患者出现≥3级毒性,无4级毒性,仅1例5级事件可能与再程放疗相关。
  • 24例OAR剂量超出ARS/ACR累积剂量推荐中仅1例与≥3级毒性相关。

核心结论

  • 每日两次加速超分割再程放疗对胸部恶性肿瘤安全有效,可提供持久局部控制与良好生存结局,毒性可接受。

研究设计与样本

  • 单中心回顾性研究,回顾自2014年以来所有每日两次胸部再程放疗病例,既往放疗计划行形变配准,采用逐体素累积EQD2(正常组织α/β=3)提取剂量学参数。

主要发现

  • 首次疗程中位EQD2(α/β=10)为60.2 Gy,再程放疗后中位随访14.2个月。
  • 再程放疗完成后中位总生存期为18.5个月,59.0%患者在2年时维持局部控制。
  • 10例(15.6%)出现≥3级毒性,无4级毒性,1例5级事件可能与再程放疗相关。
  • 24例OAR剂量超出ARS和ACR再程放疗累积剂量推荐,其中1例与≥3级毒性相关。

关键数值与推荐

  • 再程放疗剂量至少45 Gy/30次(每日两次加速超分割)。
  • 首次疗程中位EQD2(α/β=10)为60.2 Gy。
  • 正常组织累积EQD2计算采用α/β=3。
  • 毒性按CTCAE v5.0分级评估。

临床怎么用

  • 每日两次加速超分割再程放疗可作为胸部恶性肿瘤再程放疗的可行方案,需关注OAR累积剂量。
  • 即使OAR剂量超出ARS/ACR推荐,≥3级毒性关联仍较低,但需个体化评估。

局限性

  • 缺乏前瞻性对照,毒性归因判断可能存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Balancing the demands for dose-escalated re-irradiation with toxicity to organs at risk (OARs) is a challenge. Twice-daily (BID) accelerated hyperfractionated re-irradiation (re-RT) is a potential solution, yet there is no guidance for its application for thoracic malignancies. METHODS: All BID thoracic re-RT cases at our institution since 2014 were reviewed. Prior radiation courses were deformably registered. Summary plan dosimetrics were extracted using per-voxel cumulative EQD2 (α/β = 3 for normal tissues). Maximum toxicity following BID re-RT was graded per CTCAE v5.0 and assessed for relationship to radiation. Local failure (LF), progression-free survival (PFS), and overall survival (OS) were measured and compared between subgroups based on histology, re-RT dose, and metastatic status. RESULTS: Sixty-four BID re-RT cases delivering at least 45 Gy in 30 fractions were reviewed. Fifty-eight patients (90.6 %) received a prior definitive course of radiation. The median first course EQD2 (α/β = 10) was 60.2 Gy. Median follow-up after re-RT was 14.2 months. Median OS was 18.5 months from completion of BID re-RT, and 59.0 % of patients had sustained local control at two years. Ten patients (15.6 %) experienced grade ≥3 toxicity. There were no grade 4 toxicities. There was one grade 5 event possibly attributable to re-RT. Of 24 OAR doses exceeding American Radium Society (ARS) and American College of Radiology (ACR) cumulative dose recommendations for re-RT, one case was associated with grade ≥3 toxicity. CONCLUSIONS: Accelerated hyperfractionated BID re-RT is safe and effective for thoracic re-RT, providing durable local control and favorable survival outcomes with acceptable toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Doss VL, de Sousa CFPM, Hales E, et al. Efficacy and safety of twice-daily accelerated hyperfractionated re-irradiation for thoracic malignancies. Radiother Oncol. 2025. PMID: 40939679. doi:10.1016/j.radonc.2025.111130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。